Defendant
4 cases as defendant.
Lupin Limited (NSE: LUPIN; BSE: 500257) is an Indian multinational pharmaceutical company headquartered at Kalpataru Inspire, Santacruz East, Mumbai, India. It was founded in 1968 by Desh Bandhu Gupta and incorporated as a public limited company in 1983; it remains an independent, publicly traded company (not a subsidiary), with promoter/family holding around 47%. Reported FY2025 revenue was roughly ₹22,192 crore (~US$2.6 billion), with employee counts cited in the 20,000–28,000 range depending on the source and reporting date.
Operations. Lupin is one of the largest generic drugmakers globally. It develops, manufactures, and markets generic and branded formulations, active pharmaceutical ingredients (APIs), complex generics, biosimilars, and advanced drug-delivery products. Therapeutic focus areas include cardiovascular, CNS, diabetology, anti-infectives, asthma/respiratory, paediatrics, oncology, and anti-tuberculosis drugs, where it has historically been a major global supplier. It operates in the US, India, Japan, Europe, Australia, South Africa, the Philippines, Mexico, and Brazil, with US operations run through subsidiary Lupin Pharmaceuticals, Inc. (Baltimore, Maryland) and Japanese units Kyowa Pharmaceutical and I'rom. It also maintains R&D sites near Pune and Aurangabad.
Litigation posture. Lupin is an operating company and a repeat defendant in Hatch-Waxman/ANDA patent litigation. The tracked data show 1 case as defendant and 0 as plaintiff — consistent with a generic manufacturer that is routinely sued by brand owners over Paragraph IV certifications rather than an entity asserting patents offensively. Its litigation is concentrated in the District of Delaware, a common venue for ANDA actions, not the Eastern District of Texas.
Notable case. The tracked matter is Neurelis, Inc. v. Lupin Inc. et al. (D. Del., filed November 26, 2025), an ANDA infringement suit naming Lupin Inc., Lupin Limited, and Lupin Pharmaceuticals, Inc. as defendants. Public docket records indicate the dispute concerns Neurelis's VALTOCO (diazepam nasal spray) and Lupin's proposed generic, with asserted patents including U.S. 12,324,852, 12,337,061, and 12,521,400; related Neurelis filings also name co-defendant Padagis. This profile does not address the merits.
Neurelis asserted U.S. Patent 12337061 and additional patent(s) against Lupin entities in the District of Delaware, relating to ANDA No. 220394 for diazepam nasal spray strengths 5, 7.5, and 10 mg/spray. The case is pending with a bench trial set for the week of 2027-03-01.
Patent infringement action listed for U.S. Patent No. 7,968,569.
Lilly sued Lupin for infringement of US 5,023,269 in the Cymbalta/duloxetine HCl ANDA litigation. The case was dismissed by stipulation/consent order on April 27, 2011, converting Paragraph IV certifications to Paragraph III, with no appeal.
Second action against Lupin asserting the '708 patent; settled.